Evidence supporting the use of: Spirulina
For the health condition: Multiple Sclerosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Synopsis: Spirulina, a blue-green algae, has gained attention as a dietary supplement with purported immune-modulating and antioxidant properties, which has led to its investigation in autoimmune diseases such as Multiple Sclerosis (MS). The rationale for its use in MS is based on its content of phycocyanin, vitamins, minerals, and essential fatty acids, which may modulate immune function and reduce oxidative stress—factors implicated in MS pathogenesis.

Preclinical studies, particularly in experimental autoimmune encephalomyelitis (EAE, an animal model of MS), have shown that spirulina supplementation can reduce clinical severity, decrease pro-inflammatory cytokines (such as TNF-α and IFN-γ), and increase anti-inflammatory cytokines (such as IL-10). These effects are primarily attributed to its antioxidant capacity and ability to modulate immune cell activity.

However, human clinical evidence is limited. A few small pilot studies and open-label trials have suggested possible benefits in immune modulation and quality of life, but these studies are generally of low quality, with small sample sizes and lack of rigorous controls. No large-scale, randomized controlled trials have demonstrated a clear clinical benefit of spirulina in MS patients.

In summary, while there is some preclinical and early clinical evidence suggesting spirulina may have beneficial effects for people with MS, the current level of evidence is insufficient to recommend its routine use. High-quality clinical trials are needed to establish efficacy, safety, and appropriate dosing.

More about spirulina
More about Multiple Sclerosis